Robert B. Livingston, MD

Professor of Medicine and Hematologic Oncology

E-Mail Address: 
Phone Number: 
5206264175
Fax: 
5206263754
Patient Appointments: 
5206942873
Short Bio: 

Dr. Livingston is professor of medicine and hematologic oncology at the University of Arizona College of Medicine, specializing in breast cancer.

Dr. Livingston completed his medical degree and his residency in internal medicine at the University of Oklahoma College of Medicine. He completed a fellowship in developmental therapeutics at the University of Texas MD Anderson Cancer Center.

Dr. Livingston has more than 30 years of international clinical research experience in both breast and lung cancer. He formerly chaired the Breast Cancer Committee of the Southwest Oncology Group and is one of the country's strongest advocates and experts on clinical trials and clinical research.

Dr. Livingston is certified by the American Board of Internal Medicine, subspecialty of Medical Oncology.

Clinical Information
Specialty: 
Medical Oncologist
Clinical Focus: 

Breast Cancer; Breast Cancer and Pregnancy; Medical Oncology

Clinical Practice Sites: 
The University of Arizona Cancer Center - North Campus
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Associate Member
Year of Membership Acceptance: 
2006
Selected Publications: 
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res. 2011 Apr 15;17(8):2400-9. Epub 2011 Mar 1. Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011 Aug 9. [Epub ahead of print] Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat. 2011 Jul 16. Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799-805. Epub 2011 Jul 12. Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Research and Treatment Volume 130, Number 1, 123-131 Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430. Oncologist. 2012;17(2):179-87 Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM.. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012 Jun 25;2(1):34. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622. Nokes BT, Cunliffe HE, Lafleur B, Mount DW, Livingston RB, Futscher BW, Lang JE. In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene. J Cancer. 2013;4(2):104-16. doi: 10.7150/jca.5002. Epub 2013 Jan 10. Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat. 2014 Jan;143(2):351-8. doi: 10.1007/s10549-013-2797-2. Epub 2013 Dec 19.
Professional Information
Board Certifications: 
  • American Board of Internal Medicine
  • ABIM - Subspecialty of Medical Oncology
Honors: 

2008-current: Chosen by his peers to be among the "Best Doctors in America."

Dr Livingston is one of the country's strongest advocates and experts on clinical trials and clinical research. He has more than 30 years of international clinical research experience in both breast and lung cancer.

He formerly chaired the Breast Cancer Committee of the Southwest Oncology Group.

Academic Information
Fellowship: 
University of Texas (Developmental Therapeutics) 1973
Residency: 
National Institutes of Health 1970; University of Oklahoma (Internal Medicine) 1971
Medical School: 
University of Oklahoma College of Medicine, 1967